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Abstract Background:Doxylamine succinate, an ethanolamine-based antihistamine, is
used in the short-term management of insomnia because of its sedative ef-
fects. The data available on the pharmacokinetic profile of doxylamine in
humans are limited, notwithstanding that this drug has been marketed in
European countries for more than 50 years. In fact, no data on the effect of
food on the pharmacokinetic parameters of doxylamine are available.
Objective: The objective of this study was to evaluate the pharmacokinetic
parameters of doxylamine following a single oral dose of doxylamine hydrogen
succinate 25mg in healthy human subjects under fed and fasting conditions.
Study Design: This was a single-center, randomized, single-dose, laboratory-
blinded, two-period, two-sequence, crossover study.
Setting: The study was conducted in a phase I clinical unit.
Subjects and Methods: A single oral dose of doxylamine hydrogen succinate
25mg (equivalent to 17.4mg of doxylamine base) was administered to
healthy volunteers under either fed conditions (high-fat, high-calorie food
intake) or fasting conditions in each study period. The drug administrations
were separated by a wash-out period of seven calendar days. Plasma samples
were collected for up to 60 hours postdose, and plasma doxylamine concen-
trations were determined by a high-performance liquid chromatography
method with tandem mass spectrometry detection. Pharmacokinetic param-
eters were calculated using noncompartmental analysis. Safety was evaluated
through assessment of adverse events, standard laboratory evaluations, vital
signs, and 12-lead electrocardiography.
Results: In total, 24 healthy subjects (12 male and 12 female) were included in
the study. Doxylamine succinate 25mg tablets exhibited similar oral bio-
availability of doxylamine in the fasting state (mean maximum plasma drug
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concentration [Cmax] 118.21 ng/mL, coefficient of variation [CV] 19.2%; mean
area under the plasma concentration time curve from time zero to time t [AUCt]
1746.97ngh/mL, CV 31.6%) and in the fed state (mean Cmax 120.99ng/mL,
CV 15.0%; mean AUCt 1712.20ngh/mL, CV 26.7%). No statistically signif-
icant between-treatment differences were observed for any of the pharma-
cokinetic parameters under study. The fed : fasting ratios of the geometric least
squaresmeans with corresponding 90% confidence intervals for Cmax andAUCt
were within the range of 80–125%.
Conclusion: High-fat, high-calorie food intake does not affect the kinetics of
doxylamine in healthy subjects. The drug was safe and well tolerated by the
subjects in this study.
Introduction
Antihistamines were first introduced in the
1940s and represent one of the most commonly
used medications today.[1] The first-generation
antihistamine doxylamine succinate is a member
of the ethanolamine class and was introduced
into clinical use in the EU in the late 1950s. It acts
by competitively inhibiting histamine at H1 recep-
tors, the binding being readily reversible. It has
hypnotic, anticholinergic, and local anesthetic
effects, and shares the actions and uses of other
antihistamines. The effects upon the central
nervous system are fundamentally determined by
the capacity to cross the blood–brain barrier and
bind to the central H1 receptors.
[2-4] Although
sedation sometimes limits the clinical usefulness
of doxylamine when that effect is not desirable, it
also provides an additional indication, shared by
other antihistamines in the ethanolamine group:
symptomatic treatment of insomnia.[1-3,5,6]
Currently, doxylamine medicinal products have
been authorized for more than 50 years, with an
appropriate extent of use, for symptomatic treat-
ment of occasional insomnia, making doxyl-
amine a drug with a well established use. In fact,
doxylamine alone or in combination with other
drugs is available over the counter in Australia,
Belgium, Canada, France, Germany, Hungary,
Ireland, Italy, Korea, New Zealand, Poland,
Portugal, Slovenia, Spain, Switzerland, the UK,
and the US.
Dormidina has been marketed in Spain since
1990 with a unique active ingredient: doxylamine
hydrogen succinate 25mg or 12.5mg. Doxyl-
amine hydrogen succinate 25mg (salt) corresponds
to doxylamine 17.4mg (base). Doxylamine is in-
dicated for the symptomatic treatment of occa-
sional insomnia in adults aged 18 years and
over, particularly those with difficulty in falling
asleep, frequent interruptions during sleep, or
early waking in the morning. Because its market-
ing authorization was approved before the im-
plementation of the present regulatory standards,
pharmacokinetic studies of doxylamine hydro-
gen succinate in its current pharmaceutical pres-
entation (film-coated tablets) have never been
performed under fed conditions. The main ob-
jectives of this study, therefore, were to evaluate
the pharmacokinetic properties of doxylamine
following single oral dose administration of a
doxylamine hydrogen succinate 25mg film-
coated tablet to healthy human subjects under fed
and fasting conditions and to assess the rel-




Thiswas a single-center, randomized, single-dose,
laboratory-blinded, two-period, two-sequence,
crossover study. A single oral dose of doxylamine
hydrogen succinate 25mg was administered under
either fed or fasting conditions in each study
period. A 25mg dose was used, since this is the
recommended dosage regimen. No higher doses
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of the drug are currently recommended. Since the
Physician’s Desk Reference rates doxylamine as
being in pregnancy category B, it was acceptable
to include women in the present study. To ensure
that no carryover effect was observed, a wash-out
period of seven calendar days was observed be-
tween drug administrations, corresponding to
more than 10 times the expected half-life of the
moiety to be measured. It should be noted that
the randomization code was not made available
to the personnel in charge of the determination of
plasma drug concentrations (Algorithme Pharma
Inc., Laval, QC, Canada) until the analytical tab-
les were finalized and audited by the quality as-
surance department.
The protocol and the informed consent forms
were approved by an independent review board
(ETHIPRO) on June 17, 2010. All subjects vol-
untarily agreed to participate in this study and
signed the informed consent form after having
fully comprehended its contents and prior to ini-
tiation of the study procedures. This study was
performed in compliance with Good Clinical
Practice.[7]
Study Population
Subject screening procedures included informed
consent, an inclusion/exclusion check, demog-
raphy, medical history, medication history, physical
examination, height, weight, body mass index,
and a concomitant medication check. Subjects
were in good health as determined by the medical
history, physical examination (including vital
signs), 12-lead electrocardiogram, and the usual
clinical laboratory tests (hematology, biochemistry,
urinalysis), including negative HIV, hepatitis B, and
hepatitis C tests, negative screening for ethanol and
drugs of abuse in urine, and a negative pregnancy
test (for female subjects).
All participating subjects were judged to be eligi-
ble for the study when assessed against the inclusion
and exclusion criteria. Tolerability was evaluated
through assessment of adverse events (AEs),
standard laboratory evaluations, and vital signs.
The predetermined reason for excluding sub-
jects from the study was for any safety issues as
determined by the investigator. Also, subjects
could be withdrawn because of protocol violations,
administrative problems, difficulties in blood
collection, occurrence of emesis during the time
interval described in the protocol, or other reasons
described in the protocol. Furthermore, subjects
were allowed to discontinue their participation in
the study at any time. In the event of such a dis-
continuation, the subject was requested to complete
a safety assessment at the time of discontinuation,
and the reason for discontinuation was to be
documented.
Blood Sample Collection: Method of
Measurement
Blood samples were collected prior to and
0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12,
16, 24, 36, 48, and 60 hours after drug adminis-
tration. This sampling was planned in order to
provide a reliable estimate of the extent of ab-
sorption, as well as the terminal elimination half-
life (t½), and to ensure that the area under the
plasma concentration–time curve (AUC) from
time zero to time t (AUCt) was at least 80% of the
AUC from time zero extrapolated to infinity
(AUC¥). Samples were processed and stored un-
der conditions (frozen) that have been shown not
to cause significant degradation of the analyte.
The experimental samples were assayed for
doxylamine at the analytical facility of Algorithme
Pharma Inc. Sample pretreatment involved pro-
tein-precipitation extraction of doxylamine from
0.100mL of human plasma. Doxylamine-D5 was
used as the internal standard. The compounds
were identified and quantified using reverse-phase
high-performance liquid chromatography with
tandemmass spectrometry detection over a theoreti-
cal concentration range of 1.00–200.00 ng/mL. A
gradient of acetonitrile was used for the mobile
phase. A low volume was injected at room tem-
perature, using a Turbo Ionspray in positive mode,
and the mass : charge ratio (m/z) was monitored
according to the optimization of the analytical fa-
cility. Between-day variability was evaluated for all
calibrants and quality-control samples during the
study; within- and between-day variability was also
evaluated during the validation of the doxylamine
method.
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Treatment Schedule
Subjects received the investigational product
(Dormidina [Laboratorios del Dr. Esteve SA,
Barcelona, Spain]; a doxylamine hydrogen succi-
nate 25mg film-coated tablet) on two occasions
(once under fed conditions and once under fasting
conditions) according to the randomization list. The
randomization scheme was computer generated.
Food was controlled and standardized for
each treatment period and for all subjects.
The Fed State: Following an overnight fast of
at least 10 hours, subjects received a high-fat,
high-calorie breakfast 30 minutes prior to drug
administration. Afterward, a single dose of the
investigational product was administered orally
with approximately 240mL of water at ambient
temperature.
The high-fat breakfast, equivalent to approx-
imately 900kcal, consisted of about 240mL of
whole milk, two large eggs, four ounces of hash
brown potatoes (two potato patties), one English
muffin with approximately 4.5 g of butter, and
two strips of bacon. The subjects ate the total
contents of this meal in 30 minutes or less. Fur-
thermore, a standardized lunch was served at least
4 hours after dosing. A supper and a light snack
were then served at appropriate times thereafter.
Water was allowed ad libitum until 2 hours pre-
dose and from 2 hours after drug administration.
The Fasting State:The subjects fasted overnight
for at least 10 hours prior to drug administration.
A single dose of the investigational product was
thereafter administered orally with approximately
240mL of water at ambient temperature.
Fasting continued for at least 4 hours follow-
ing drug administration, after which a stand-
ardized lunch was served. A supper and a light
snack were also served at appropriate times
thereafter, but not before 9 hours after dosing.
Water was allowed ad libitum until 2 hours pre-
dose and from 2 hours after drug administration.
Statistical Analysis
Sample Size
The sample size was calculated, taking into
consideration that the intrasubject variations in
the maximum plasma drug concentration (Cmax)
and AUCt following a single dose of doxylamine
appear to be around 10%. Therefore, it was esti-
mated that 24 subjects were sufficient to evaluate
the bioavailability of a single 25mg dose of dox-
ylamine after single oral dose administration un-
der fed and fasting conditions.
Statistical Comparison
Descriptive statistics were used to summarize
AEs, safety results, and demographic variables
(age, height, weight, and body mass index).
Pharmacokinetic parameters such as Cmax, the time
to reach Cmax (tmax), AUCt, AUC¥, AUCt :AUC¥,
the elimination rate constant (ke), and t½ were
calculated. For statistical analysis of relative
bioavailability, the main pharmacokinetic parame-
ters of interest were Cmax and AUCt. The natural
logarithmic transformation of Cmax, AUCt, and
AUC¥ was used for all statistical inferences. The
main absorption and disposition parameters were
estimated using a noncompartmental approach
with a log-linear terminal phase assumption. The
trapezoidal rule was used to estimate the area under
the concentration–time curve, and the terminal
phase was estimated by maximizing the coefficient
of determination estimated from the log-linear re-
gression model. They were not to be estimated for
individual concentration–time profiles, where the
terminal log-linear phase could not be reliably
characterized. The mean, median, minimal value,
maximal value, standard deviation, and coefficient
of variation were calculated for plasma concen-
trations at each individual timepoint and for all
pharmacokinetic parameters. tmax was analyzed
using a nonparametric approach. Testing of fixed
period, sequence, and treatment effects was based
on theWilcoxon rank sum test (theMann–Whitney
U-test). All other untransformed and log-normal
(ln)-transformed pharmacokinetic parameters were
statistically analyzed using a random analysis of
variance (ANOVA) model. The fixed factors in-
cluded in this model were the treatment received,
the period in which it was given, and the sequence
in which each treatment was received. A random
factor was also added for the subject effect (nested
within sequence).
The sequence, period, and treatment effects
were assessed at the 5% two-sided level. The in-
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trasubject coefficient of variation was calculated,
where the mean square error was obtained from
the ANOVAmodel of the ln-transformed param-
eters. If a pharmacokinetic parameter could not
be determined for one period in an individual
subject, that subject was excluded from that par-
ticular statistical comparison.
To assess bioavailability, the ratios of the
geometric least squares (LS) means with corre-
sponding 90% confidence intervals were calculated
from the exponential of the difference between
the fed and fasting conditions for the ln-transformed
parameters Cmax and AUCt.
Furthermore, an exploratory analysis was
carried out to explore the sex effect.
Statistical and pharmacokinetic analyses were
generated using Kinetic, a software application
developed at Algorithme Pharma Inc., and SAS




A total of 24 healthy volunteers were included
(12 male and 12 female), with a median age of
36 years (range 20–53), weight of 75.4 kg (range
53.4–99.7), height of 173 cm (range 149–188), and
body mass index of 25.5 kg/m2 (range 19.6–28.6).
Twenty-one subjects (88%) were White, two (8%)
were Black, and one (4%) was Asian.
Of these 24 subjects, 23 completed the cross-
over design and received a single oral dose of the
assigned treatment on day 1 and day 8. One
subject was withdrawn before dosing in period 2
for safety reasons (eczema of severe intensity) and
received only one single oral dose of doxylamine
hydrogen succinate under fed conditions. This
subject was excluded from the statistical com-
parison of relative bioavailability but was in-
cluded in the safety analysis.
Treatment Compliance
All subjects took the study medication accord-
ing to the protocol. The investigational product
was administered under the supervision of the
qualified investigator or his designees. The film-
coated tablet was to be swallowed whole and was
not to be chewed or broken. Following adminis-
tration of the drug, each subject’s hands and
mouth were checked in order to confirm the
consumption of the medication. The physician in
charge remained at the clinical site for at least the
first 4 hours following each drug administration
and remained available at all times during the
entire period of the study.
Pharmacokinetic Assessments
Tables I and II depict the doxylamine pharm-
acokinetic results: Cmax, tmax, AUCt, AUC¥,
AUCt : AUC¥, ke, and t½ in both the fed and
fasting states. No statistically significant be-
tween-treatment differences were observed for
any of the pharmacokinetic parameters under
study. The usual criteria used to assess the food
effect of the test formulation were fulfilled. The
fed : fasting ratio of the geometric LS means and
corresponding 90% confidence intervals for Cmax
and AUCt were within the range of 80–125%.
Figures 1 and 2 show the linear and logarithmic
profiles of the mean plasma concentrations of
doxylamine. Table III shows the main pharmaco-
kinetic parameters of doxylamine, analyzed by
sex.
Tolerability and Safety
No deaths or serious AEs were reported during
this study. Twenty-one (87.5%) of the 24 subjects
included in the study experienced a total of 54AEs.
Seventeen subjects (70.8%) reported 33 AEs
(five different system organ classes [SOCs] and
eight different preferred terms [PTs]) after single-
dose administration of the test product under fed
conditions, and 15 subjects (65.2%) reported 21
AEs (five different SOCs and six different PTs)
after single-dose administration of the test prod-
uct under fasting conditions. The most frequently
reported AE was somnolence (reported in 70.8%
of the subjects under fed conditions and in 56.5%
of the subjects under fasting conditions).
The severity of AEs ranged from mild to se-
vere. Five severe AEs (four in the fed state: ecze-
ma, headache, somnolence [two occurrences]; one
in the fasting state: somnolence) were observed
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during the study. Of all AEs, four (blood potas-
sium level increased, feeling cold, and hypo-
esthesia [two occurrences]) were unexpected and
possibly drug related.
No significant alterations were found in the
laboratory evaluations and the electrocardio-
gram repeated at the end of the study.
Discussion
To our knowledge, this is the first time that the
effect of food on the pharmacokinetic parameters
of doxylamine has been studied. The results of
this study show that the fed : fasting ratios of the
geometric LS means and corresponding 90%
confidence intervals for Cmax and AUCt were
within the range of 80–125%. Consequently, the
test formulation of doxylamine hydrogen succi-
nate 25mg film-coated tablets manufactured by
Laboratorios del Dr. Esteve SA (Barcelona,
Spain) was judged to be bioequivalent under fed
and fasting conditions.
Data available on the pharmacokinetic profile
of doxylamine in humans are limited, notwith-
standing that this drug has been marketed in
European countries for more than 50 years. In
fact, the available studies on pharmacokinetic
parameters after an oral dose of doxylamine suc-
cinate 25mg were published more than 20 years
ago.[6,8-10] It should be noted that this phase I
clinical trial was one of the first to be performed
in compliance with Good Clinical Practice and
under the current regulatory standards. In the
present study conducted under fasting and fed
conditions, the pharmacokinetic parameters of
doxylamine were not significantly affected by
high-fat, high-calorie food intake. No statistically
relevant differences in pharmacokinetic parame-
ters between the two states were found. Although
some slight differences in some pharmacokinetic
parameters (without clinical significance) might
be found in comparison with other published
studies, the overall results of this study are in line
with studies performed with oral doses of doxyl-
amine succinate 25mg tablets[6,8,9] and with oral
doses of doxylamine succinate 20mg solution.[10,11]
These slight differences could be explained by the
analytical method that was used.[11,12] On the other
hand, the fact that no significant sequence effect
was observed in either the fasting or the fed treat-
ment period of the study indicates that the washout
period was appropriate and that no carryover ef-
fect was present. The effect of sex was studied as
Table I. Summary of the main pharmacokinetic parameters of
doxylamine
Parameter Mean [CV (%)]
Feda Fastinga
Cmax (ng/mL) 120.99 [15.0] 118.21 [19.2]
ln Cmax 4.7846 [3.2] 4.7559 [3.9]
tmax (h)
b 2.50 [41.7] 2.00 [27.7]
AUCt (ngh/mL) 1712.20 [26.7] 1746.97 [31.6]
ln AUCt 7.4150 [3.3] 7.4279 [3.6]
AUC¥ (ngh/mL) 1798.14 [29.6] 1830.05 [33.6]
ln AUC¥ 7.4580 [3.6] 7.4698 [3.8]
AUCt : AUC¥ (%) 95.84 [3.2] 95.91 [2.2]
ke (h
-1) 0.0544 [22.3] 0.0553 [24.4]
t½ (h) 13.49 [28.1] 13.11 [19.5]
a The p-values for all comparisons between the fed and fasting
states were nonsignificant (i.e., p ‡ 0.05).
b For tmax, median values are presented, and the statistical
analysis is based on a nonparametric approach.
AUC= area under the plasma concentration–time curve;AUCt=AUC
from time zero to time t; AUC¥ =AUC from time zero extrapolated to
infinity; Cmax=maximum plasma drug concentration; CV= coefficient
of variation; ke= elimination rate constant; ln= log-normal; t½= elim-
ination half-life; tmax= time to reach Cmax.
Table II. Standards for comparative bioavailability of doxylamine
Parameter Intrasubject Geometric LS mean Fed : fasting ratioa
CV (%) Fed Fasting (% [90% CI])
Cmax 8.9 119.59 ng/mL 116.07 ng/mL 103.03 [98.50–107.77]
AUCt 6.2 1657.34 ngh/mL 1678.16 ngh/mL 98.76 [95.72–101.90]
a The p-values for all comparisons between the fed and fasting states were nonsignificant (i.e., p ‡0.05).
AUCt =area under the plasma concentration–time curve from time zero to time t; CI = confidence interval; Cmax =maximum plasma drug
concentration; CV = coefficient of variation; LS = least squares.
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a descriptive analysis. No statistically significant
differences in the pharmacokinetic parameters be-
tween male and female subjects were observed in
either the fasting or the fed states. It should be
noted that female subjects had a longer tmax in the
fed state than in the fasting state.
Doxylamine succinate is available as an over-
the-counter hypnotic agent and in many cough
and cold formulations. The healthy subjects in-
cluded in this study were young (between 20 and
53 years old). The absorption, distribution, me-
tabolism, and excretion of doxylamine did not
seem to be significantly affected by the age or by
the sex of the subjects, although the clearance of
doxylamine could be reduced in elderly men but










































Fig. 2. Logarithmic profile of the mean plasma concentrations of doxylamine in the fed and fasting states. ln = log-normal.
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no sex effect was observed. The results obtained
in this study could be extrapolated to the general
population, although studies in an elderly popu-
lation would be necessary.
Overall, the doxylamine hydrogen succinate
25mg film-coated tablet was generally safe and
well tolerated by the subjects in this study. It
should be noted that most of the subjects experi-
enced somnolence under both fasting and fed
conditions when administered doxylamine hy-
drogen succinate 25mg, although somnolence
and sleep induction seemed to be more frequent
under fed conditions.
Certain aspects of the study design should be
considered before drawing conclusions for future
users of doxylamine hydrogen succinate, as the
open-label, single-dose design and the fact that
the study population consisted of healthy subjects
could lead to underestimation or overestimation
of the generalizability of the results beyond the
population and conditions that were studied.
Conclusion
The usual criteria used to assess the food effect
of the test formulation were fulfilled. The fed :
fasting ratio of the geometric LS means and the
corresponding 90% confidence intervals for Cmax
and AUCt were within the range of 80–125%.
Doxylamine hydrogen succinate 25mg film-
coated tablets are judged to be bioequivalent
under fed and fasting conditions. Consequently,
high-fat, high-calorie food intake does not affect
the kinetics of doxylamine in healthy subjects.
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